Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC > MCNA a Blockbuster Drug without Competition
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by investderpon Nov 02, 2015 4:11pm
214 Views
Post# 24251359

RE:RE:RE:MCNA a Blockbuster Drug without Competition

RE:RE:RE:MCNA a Blockbuster Drug without Competition Blockbuster is like a broken clock, he's been pumping TST for a few months now.  I guess this is one of the two times a day he's right though (about promoting TST - not the prostate/breast cancer drivel).
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities